OncoMatch/Clinical Trials/NCT06505369
Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients
Is NCT06505369 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for multiple myeloma.
Treatment: Daratumumab · Bortezomib · Lenalidomide · Dexamethasone · Talquetamab · Teclistamab — This is Phase 2, open-label, multicentre, non-randomised study evaluating participants with newly diagnosed MM eligible for high-dose therapy. The goal of the study is to determine if consolidation with T-cell redirectors - Talquetamab and Teclistamab in sequence will improve the response depth: increase MRD negative CR rate.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Endocrine / hormonal
Other
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: systemic therapy or stem cell transplantation for any plasma cell dyscrasia
Exception: emergency use of a short course (equivalent of dexamethasone 40 mg/day for a maximum 4 days) of corticosteroids before treatment
Prior or current systemic therapy or stem cell transplantation for any plasma cell dyscrasia, with the exception of emergency use of a short course (equivalent of dexamethasone 40 mg/day for a maximum 4 days) of corticosteroids before treatment.
Lab requirements
Blood counts
Hemoglobin ≥8 g/dL; Platelets ≥75×10^9/L; ANC ≥1.0×10^9/L
Kidney function
eGFR ≥30 mL/min
Liver function
AST and ALT ≤2.5×ULN; Total bilirubin <1.5×ULN
Have clinical laboratory values meeting the following criteria: Hemoglobin ≥8 g/dL; Platelets ≥75×10^9/L; ANC ≥1.0×10^9/L; AST and ALT ≤2.5×ULN; eGFR ≥30 mL/min; Total bilirubin <1.5×ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06505369 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages